Patents by Inventor Jan Haas

Jan Haas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPIGENOME-WIDE ASSOCIATION STUDY IDENTIFIES CARDIAC DEVELOPMENTAL GENE PATTERNING AND A NOVEL CLASS OF BIOMARKERS FOR HEART FAILURE
    Publication number: 20200181703
    Abstract: The present invention relates to a method of determining markers for a disease from a patient, wherein information from epigenomics and/or the transcriptome from peripheral blood and a diseased tissue or information from epigenomics and the transcriptome from peripheral blood or a diseased tissue is used for obtaining the markers, as well as a method of determining a risk for a disease in a patient using the markers obtained thereby.
    Type: Application
    Filed: July 6, 2017
    Publication date: June 11, 2020
    Applicant: Siemens Healthcare GmbH
    Inventors: Andreas Emanuel POSCH, Benjamin MEDER, Jan HAAS, Hugo A. KATUS, Maximilian WUERSTLE, Farbod SEDAGHAT-HAMEDANI, Andreas KELLER, Cord Friedrich STAEHLER
  • Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
    Patent number: 9938580
    Abstract: The present invention relates to the use of DNA methylation profiles of patient samples for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, wherein the DNA methylation profile of the patient sample is compared with the DNA methylation profile of a control sample, and wherein a difference in the DNA methylation profile of the patient sample compared to the control sample is indicative of a heart disease or of the risk for developing a heart disease or for a prediction of therapy effects or therapy outcome. The present invention further relates to methods for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, comprising determining the DNA methylation profile in a patient sample comprising genomic DNA from heart cells, heart tissue or peripheral blood; and comparing the DNA methylation profile in the patient sample with the DNA methylation profile from a normal subject not having a heart disease or having a normal heart function.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 10, 2018
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Benjamin Meder, Jan Haas, Hugo A. Katus
  • Epigenetic Signatures as Marker for Cardiomyopathies and Myocardial Insufficiencies
    Publication number: 20150065355
    Abstract: The present invention relates to the use of DNA methylation profiles of patient samples for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, wherein the DNA methylation profile of the patient sample is compared with the DNA methylation profile of a control sample, and wherein a difference in the DNA methylation profile of the patient sample compared to the control sample is indicative of a heart disease or of the risk for developing a heart disease or for a prediction of therapy effects or therapy outcome. The present invention further relates to methods for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, comprising determining the DNA methylation profile in a patient sample comprising genomic DNA from heart cells, heart tissue or peripheral blood; and comparing the DNA methylation profile in the patient sample with the DNA methylation profile from a normal subject not having a heart disease or having a normal heart function.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 5, 2015
    Inventors: Benjamin Meder, Jan Haas, Hugo A. Katus